Search alternatives:
significant improvements » significant improvement (Expand Search)
improvements decrease » improvements increased (Expand Search), improvements across (Expand Search)
side decrease » sizes decrease (Expand Search), fid decreased (Expand Search), step decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
Showing 1 - 20 results of 10,155 for search '(( significant improvements decrease ) OR ( significant ((side decrease) OR (we decrease)) ))', query time: 0.56s Refine Results
  1. 1
    The linearly decreasing convergence factor a.

    The linearly decreasing convergence factor a. by Junhao Wei (6816803)

    Published 2025
    Save to List
    Saved in:
  2. 2
    Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side.

    Stability differences between condition 1 and other conditions across participants on the non-hemiparetic side (NHP) side. by Hyung Suk Yang (20442438)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  3. 3
    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  4. 4
    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  5. 5
    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
    Save to List
    Saved in:
  6. 6
    Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side.

    Stability differences between condition 1 and other conditions across participants on the hemiparetic (HP) side. by Hyung Suk Yang (20442438)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 7
    Overview of the WeARTolerance program.

    Overview of the WeARTolerance program. by Ana Beato (20489933)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 8
    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count.

    Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque count. by Francesca Catto (21253435)

    Published 2025
    “…Additionally, the plots on the right side display the average plaque count across the cohorts. …”
    Save to List
    Saved in:
  9. 9
    Brain regions with significantly decreased activations for the Raven task are shown in blue.

    Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

    Published 2025
    Save to List
    Saved in:
  10. 10
    Schematic representation of the study protocol.

    Schematic representation of the study protocol. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Baseline characteristics.

    Baseline characteristics. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Comparison within groups.

    Comparison within groups. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Comparison before and after the experiment in each group.

    Comparison before and after the experiment in each group. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Data ste.

    Data ste. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Comparison of data after the experiment.

    Comparison of data after the experiment. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Correlation diagram of each parameter in each group.

    Correlation diagram of each parameter in each group. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Recruitment process.

    Recruitment process. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Comparison of post-experimental outcome measures.

    Comparison of post-experimental outcome measures. by Neng Pan (5262032)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side.

    ALK inhibitors (Positive control) and ABT199 (Proposed binding) in complex with the ALK active side. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Save to List
    Saved in:
  20. 20
    Bluetooth beacons with colour coded lanyards.

    Bluetooth beacons with colour coded lanyards. by J Mark Ansermino (13958512)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: